Literature DB >> 8780837

The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study.

S H Willemsen-Swinkels1, J K Buitelaar, H van Engeland.   

Abstract

In a double-blind placebo-controlled crossover trial 23 autistic children, aged 3-7 years, were treated with a mean daily dosage of 1 mg/kg naltrexone for 4 weeks. Drug effects were monitored with behavior checklists rated by parents and teachers, and ethological playroom observations. On average, parents' checklists and playroom data could not differentiate between naltrexone treatment and placebo treatment; however, teachers significantly favored naltrexone treatment. They reported a decrease in hyperactivity and irritability. No effects of naltrexone on social and stereotypic behavior could be demonstrated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8780837     DOI: 10.1016/0006-3223(95)00297-9

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  13 in total

1.  Brief report: six months continuation treatment in naltrexone-responsive children with autism: an open-label case-control design.

Authors:  S H Willemsen-Swinkels; J K Buitelaar; I A van Berckelaer-Onnes; H van Engeland
Journal:  J Autism Dev Disord       Date:  1999-04

2.  Brief report: case reports on naltrexone use in children with autism: controlled observations regarding benefits and practical issues of medication management.

Authors:  P G Williams; A Allard; L Sears; N Dalrymple; A S Bloom
Journal:  J Autism Dev Disord       Date:  2001-02

Review 3.  Autism: current theories regarding its pathogenesis and implications for rational pharmacotherapy.

Authors:  J K Buitelaar; S H Willemsen-Swinkels
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

Review 4.  Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders.

Authors:  M G Aman; K S Langworthy
Journal:  J Autism Dev Disord       Date:  2000-10

5.  Treatment of Autism Spectrum Disorder in Children and Adolescents.

Authors:  Melissa DeFilippis; Karen Dineen Wagner
Journal:  Psychopharmacol Bull       Date:  2016-08-15

Review 6.  [Psychopharmacology of autism spectrum disorders].

Authors:  L Poustka; T Banaschewski; F Poustka
Journal:  Nervenarzt       Date:  2011-05       Impact factor: 1.214

Review 7.  Opiate antagonists in children and adolescents.

Authors:  N Chabane; M Leboyer; M C Mouren-Simeoni
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 8.  Medication treatment in subjects with autistic spectrum disorders.

Authors:  J K Buitelaar; S H Willemsen-Swinkels
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 9.  Pharmacotherapy of pervasive developmental disorders in children and adolescents.

Authors:  Gabriele Masi
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

10.  Self injurious behavior in autism: clinical aspects and treatment with risperidone.

Authors:  R Canitano
Journal:  J Neural Transm (Vienna)       Date:  2005-08-03       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.